To achieve above average, consistent and stable high returns by investing in a concentrated portfolio of 30-55 (maximum 60) equities from the European markets and to perform in a top quartile profile when measured against competing funds in the same sector.
Name | % Net Assets |
---|---|
AstraZeneca | 4.5% |
Roche Holdings | 4.1% |
Sanofi-Aventis | 3.8% |
KPN Kon | 3.6% |
Swedish Match | 3.5% |
UBS | 3.2% |
ING Groep | 3.0% |
Smurfit Kappa | 2.8% |
Aegon | 2.8% |
TomTom | 2.7% |
Key | % Net Assets |
---|---|
AstraZeneca | 4.5% |
Roche Holdings | 4.1% |
Sanofi-Aventis | 3.8% |
KPN Kon | 3.6% |
Other | 84% |
Date | n/a |
---|---|
Bid | 0.00 |
Offer | 0.00 |
Currency | n/a |
Change | 0.00 |
% | n/a |
YTD change | 0.00 |
YTD % | n/a |
Fund Inception | 12/05/2005 |
---|---|
Fund Manager | Barry Norris |
TER | 1.78 (30-Mar-2012) |
Minimum Investment | |
---|---|
Initial | 500 |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | 5.25% |
Annual Mang't | 1.75% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | 0.10 |
You are here: research